Oncosil Medical (OSL) H2 2026 earnings summary

Executive summary

• Achieved major regulatory milestones, including TGA approval in Australia and FDA HDE approval for the OncoSil™ device in the US for distal cholangiocarcinoma, enabling entry into new markets.

• Commercial adoption accelerated, with first patient treatments in Portugal, Germany, and the UK, and a 53% increase in unit sales year-over-year.

• Completed significant capital raises totaling $13.5 million before costs, strengthening the cash position and supporting ongoing R&D and commercial expansion.

Financial highlights

• Revenue from ordinary activities increased 43.9% to $1,684,978 compared to FY25.

• Other income, primarily from R&D tax incentives, rose 678.2% to $3,543,737.

• Net loss after tax decreased 28.1% to $(10,860,122) (FY25: $(15,099,844)).

• Cash and cash equivalents at year-end were $6,475,890, up from $5,109,692.

• Customer receipts grew 179% year-over-year to $2.1 million.

Outlook and guidance

• Anticipates commercial launches in Australia and the US in the first half of calendar 2027.

• Focus on expanding regulatory approvals for new indications and delivery methods, including FOLFIRINOX combination and percutaneous administration.

• Expects R&D cash outflows to decline from Q2 FY27 as major trials conclude.

• Targeting annualized cost savings of $3.4–$3.9 million from FY27.